PlainPharmaWatch

CMS Open Payments · Program Year 2024

Curonix LLC

Curonix LLC reported $810,140.62 across General Payments, Research, and Ownership to 6,645 physicians and teaching hospitals across 6,664 transactions.

$810.1K Above-median payer
All-tracks total
6,664 Top quartile volume
Transactions
6,645 Top quartile reach
Recipients
−$375.3K
General Payments vs PY2023

Curonix LLC reported $810,140.62 across all CMS Open Payments tracks (General + Research + Ownership) to 6,645 physicians and teaching hospitals in Program Year 2024 - ranking #669 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $754,773.92, averaging $121.92 per recipient.

How Curonix LLC's $810.1K all-tracks total breaks down

Curonix LLC's payment reach score

Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.

Overall reach score

F

46/100

Total payments

F

17/100

Transaction volume

D

58/100

Physician reach

D

60/100

Payment type diversity

D

50/100

Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.

CMS Sunshine Act warrant

Manufacturer curonix-llc Curonix LLC

$810.1K · #669/1,925 · 0.0% industry · PY2024

  • TOT $810.1K
  • RANK #669
  • SHARE 0.0%
  • TXN 6,664
  • RCP 6,645
  • CAT 4
  • GEN $754.8K
  • ΔGEN −$375.3K
  • TOP1 8.1%
  • PY 2024

Nearest volume peer: Central California Surgical Distributors, LLC ($814.0K)

Kardium Inc.$816.9KAesculap AG$815.8KCentral California Surgical …$814.0KCuronix LLC (this)$810.1KPrecision Spine, Inc.$802.9K
All-tracks payment totals near Curonix LLC (CMS Open Payments PY2024)

Curonix LLC sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →

Release-over-release change

General Payments changed from PY2023 to PY2024

Curonix LLC's CMS-reported General Payments decreased by $375.3K (−33.2%) from PY2023 to PY2024.

How this year-over-year comparison is scoped

The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.

CMS source labels for this exact identifier: PY2022: CURONIX LLCPY2023: CURONIX LLCPY2024: Curonix LLC. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.

Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.

General Payments: PY2023 vs PY2024

Annual CMS-reported totals for this company, not an all-category Open Payments total

PY2023$1.1MPY2024$754.8K
PY2023
$1,130,113.07
PY2024
$754,773.92

What the Data Shows for Curonix LLC

CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For Curonix LLC, that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.

"Consulting Fee" leads the 4-category general-payment breakdown below at $362.1K (48.0% of General Payments, 177 transactions) - see our methodology for how research and ownership payments are reported separately.

General Payment Breakdown by Type

Curonix LLC made 4 types of general payments. "Consulting Fee" is the largest category at $362.1K, 48.0% of General Payments.

Curonix LLC reports 4 general-payment categories - the top three are Consulting Fee (48.0%), Food and Beverage (28.9%), and Travel and Lodging (22.3%). The remaining 1 category make up 0.9% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.

How Curonix LLC divides its payments

Ranked by total dollars reported per category

1. Consulting Fee$362.1K2. Food and Beverage$217.9K3. Travel and Lodging$168.2K4. Education$6.5K
Payment Type Amount Transactions
Consulting Fee $362.1K 177
Food and Beverage $217.9K 5,314
Travel and Lodging $168.2K 958
Education $6.5K 196

Recipient Concentration in General Payments

The five largest recipient relationships account for $237,401.53 (31.5%) of $754,773.92 in this company's General Payments records across 2,864 recipients.

General Payments scope note

Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.

Largest General-Payment relationships for Curonix LLC

The five named recipients with the highest reported General Payments from this company

Jonathan Edward Silverman$61.0KAlaa Abd-Elsayed$51.0KMatthias Wiederholz$49.4KHesham Elsharkawy$38.1KJordan Tate$37.9K
  1. 1

    Jonathan Edward Silverman

    $60,980.39 across 71 reported transactions

  2. 2

    Alaa Abd-Elsayed

    $51,025.72 across 43 reported transactions

  3. 3

    Matthias Wiederholz

    $49,409.39 across 48 reported transactions

  4. 4

    Hesham Elsharkawy

    $38,126.40 across 33 reported transactions

  5. 5

    Jordan Tate

    $37,859.63 across 38 reported transactions

Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.

Spend vs. Concentration

Curonix LLC ranks #669 of 1,925 by total payments (top 35% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,503 of 1,838 by HHI (bottom 18% least concentrated), a wider distribution than most similarly sized payers.

02.14.26.38.4248.2252.6257261.4265.8Total payments ($M)Concentration (HHI, 0-10,000)
Curonix LLC (highlighted) among its 12 nearest HHI-concentration neighbors, Program Year 2024. Dashed lines mark this neighborhood's median payment total and median HHI. Hover a point for the company name. Source: company_concentration (CMS Open Payments general-payment recipients).
View all 12 companies in this HHI neighborhood as a list

Similarly Concentrated Companies

Companies whose General Payments are spread across recipients about as (un)evenly as Curonix LLC's, measured by the same HHI concentration index above, not by payment size.

What HHI 2,500 means here

2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Curonix LLC.

Companies with Similar Payment Volumes

Open a profile or compare a similar company's CMS-reported payment pattern with Curonix LLC.

Showing 6 of 1,924 companies with CMS-reported payment data.

Put this to use

Curonix LLC ranks #669 of 1,925 by all-tracks total payments, led by "Consulting Fee".

Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.

Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer

This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.

View saved (companies)
Download Curonix LLC's data (CSV)
Embed this widget

Copy this snippet to embed a live-linked card on your own site.

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.